These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28717715)

  • 1. Compulsory Licenses for Cancer Drugs: Does Circumventing Patent Rights Improve Access to Oncology Medications?
    Bognar CLFB; Bychkovsky BL; Lopes GL
    J Glob Oncol; 2016 Oct; 2(5):292-301. PubMed ID: 28717715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trade-Related Aspects of Intellectual Property Rights Flexibilities and Public Health: Implementation of Compulsory Licensing Provisions into National Patent Legislation.
    McGIVERN L
    Milbank Q; 2023 Dec; 101(4):1280-1303. PubMed ID: 37646392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affordability versus innovation: Is compulsory licensing the solution?
    Pandey E; Paul SB
    Int J Risk Saf Med; 2019; 30(4):233-247. PubMed ID: 31658067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AIDS, essential medicines, and compulsory licensing.
    Berman D
    J Int Assoc Physicians AIDS Care; 1999 Apr; 5(4):24-5. PubMed ID: 11367046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines.
    Mermelstein S; Stevens H
    Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Learning from practice: compulsory licensing cases and access to medicines.
    Stirner B
    Pharm Pat Anal; 2012 Nov; 1(5):555-75. PubMed ID: 24236925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRIPS, the Doha Declaration and increasing access to medicines: policy options for Ghana.
    Cohen JC; Gyansa-Lutterodt M; Torpey K; Esmail LC; Kurokawa G
    Global Health; 2005 Dec; 1():17. PubMed ID: 16336685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Divergence and Convergence of Royalty Determinations between Compulsory Licensing under the TRIPS Agreement and Ongoing Royalties as an Equitable Remedy.
    Shore D
    Am J Law Med; 2020 Mar; 46(1):55-88. PubMed ID: 32460655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Access to medicines and domestic compulsory licensing: learning from Canada and Thailand.
    Kuek V; Phillips K; Kohler JC
    Glob Public Health; 2011; 6(2):111-24. PubMed ID: 20234967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines?
    Kerry VB; Lee K
    Global Health; 2007 May; 3():3. PubMed ID: 17524147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COMPULSORY LICENSING IN CONTEXT OF THE COVID-19 PANDEMIC AS A TOOL FOR ENSURING THE BALANCE BETWEEN RIGHTS-HOLDERS' AND SOCIETY'S INTERESTS.
    Chepys O
    Georgian Med News; 2020 Nov; (308):160-165. PubMed ID: 33395660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Access to critical medicines: When are compulsory licenses effective in price negotiations?
    Ramani SV; Urias E
    Soc Sci Med; 2015 Jun; 135():75-83. PubMed ID: 25957163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union:
    't Hoen EFM; Boulet P; Baker BK
    J Pharm Policy Pract; 2017; 10():19. PubMed ID: 28670455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of intellectual property rights in treatment access: challenges and solutions.
    't Hoen E; Passarelli CA
    Curr Opin HIV AIDS; 2013 Jan; 8(1):70-4. PubMed ID: 23201855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legal and policy foundations for global generic competition: Promoting affordable drug pricing in developing societies.
    Zapatero Miguel P
    Glob Public Health; 2015; 10(8):901-16. PubMed ID: 25737069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An exploration of compulsory licensing as an effective policy tool for antiretroviral drugs in India.
    Jain D; Darrow JJ
    Health Matrix Clevel; 2013; 23(2):425-57. PubMed ID: 24341078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poverty, health & intellectual property rights with special reference to India.
    Satyanarayana K; Srivastava S
    Indian J Med Res; 2007 Oct; 126(4):390-406. PubMed ID: 18032814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.